Please login to the form below

Not currently logged in
Email:
Password:

enasidenib

This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.

Novartis gets EU nod for leukaemia drug Rydapt

Novartis gets EU nod for leukaemia drug Rydapt

or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.

Latest news

  • Celgene, Agios get FDA OK for leukaemia drug Idhifa Celgene, Agios get FDA OK for leukaemia drug Idhifa

    Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

  • Celgene bags US priority review for cancer metabolism drug Celgene bags US priority review for cancer metabolism drug

    Celgene bags US priority review for cancer metabolism drug. First approval for enasidenib could be just six months away. ... Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute myeloid

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics